Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

CellSource Co stock

4880.T
JP3423580004

Price

1,127.00
Today +/-
+0.12
Today %
+1.79 %
P

CellSource Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the CellSource Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the CellSource Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the CellSource Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze CellSource Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

CellSource Co Stock Price History

DateCellSource Co Price
11/19/20241,127.00 undefined
11/18/20241,107.00 undefined
11/15/20241,131.00 undefined
11/14/20241,131.00 undefined
11/13/20241,141.00 undefined
11/12/20241,162.00 undefined
11/11/20241,164.00 undefined
11/8/20241,174.00 undefined
11/7/20241,169.00 undefined
11/6/20241,191.00 undefined
11/5/20241,177.00 undefined
11/1/20241,188.00 undefined
10/31/20241,187.00 undefined
10/30/20241,182.00 undefined
10/29/20241,188.00 undefined
10/28/20241,174.00 undefined
10/25/20241,140.00 undefined
10/24/20241,195.00 undefined
10/23/20241,210.00 undefined
10/22/20241,227.00 undefined

CellSource Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CellSource Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CellSource Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CellSource Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CellSource Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CellSource Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CellSource Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CellSource Co’s growth potential.

CellSource Co Revenue, EBIT and net profit per share

DateCellSource Co RevenueCellSource Co EBITCellSource Co Net Income
2026e5.52 B undefined0 undefined620.78 M undefined
2025e4.82 B undefined0 undefined361.06 M undefined
2024e4.42 B undefined0 undefined425.41 M undefined
20234.51 B undefined1.22 B undefined923.14 M undefined
20224.27 B undefined1.57 B undefined1.02 B undefined
20212.92 B undefined992.44 M undefined651.4 M undefined
20201.86 B undefined415.55 M undefined274.08 M undefined
20191.61 B undefined326.94 M undefined199.61 M undefined
20181.21 B undefined295.09 M undefined193.4 M undefined
2017519.06 M undefined159.16 M undefined111.4 M undefined

CellSource Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e
0.521.211.611.862.924.274.514.424.825.52
-133.5332.9215.1557.5246.245.55-1.938.9314.51
57.6172.1971.5767.8270.9871.7170.6272.0166.1157.73
0.30.881.151.262.073.063.19000
0.110.190.20.270.651.020.920.430.360.62
-73.873.1137.69137.5956.22-9.24-53.95-15.0671.75
12.9612.9613.0619.1319.2119.2119.26000
----------
Details

Keystats

ⓘ

Revenue and Growth

The CellSource Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the CellSource Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2017201820192020202120222023
             
0.130.251.331.762.413.124.78
49.91136.59134.17224.92307.43649.8361.49
0000000
76.43123.52164.97132.33165.55227.02305.93
30.2528.7421.7351.6563.5376.99140.74
0.290.541.652.172.954.085.59
24.3943.7473.0282.85110.12166.26658.74
0000143.93171.43152.04
004.74.7000.17
04.434.245.4711.1310.4819.81
0000000
16.75107.05105.8593.21154.35174.12459.8
0.040.160.190.190.420.521.29
0.330.71.842.353.374.66.88
             
0.090.090.590.670.680.691.43
000.50.580.590.61.34
0.120.310.510.791.452.53.43
0001122
00000.153.0514.03
0.210.41.612.042.723.796.2
7.6431.4814.6329.8841.03109.6975.46
19.0842.843.5379.98123.26149.51132.71
92.85221.48169.05195.49468.62554.95223.73
0000000
003.043.191.1020.25
119.57295.76230.25308.53634814.15452.16
004.291.10077.29
0000000
0000110148.29
004.291.1110225.58
119.57295.76234.54309.63645814.15677.74
0.330.71.842.353.374.66.88
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of CellSource Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand CellSource Co's financial health and stability.

Assets

CellSource Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that CellSource Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of CellSource Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into CellSource Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
0.160.290.30.411.011.581.24
10132026304563
0000000
-61-98-202-155-158-844-505
147346196348
0000000
28215976167486689
109213195330898847846
-7-24-53-32-61-99-359
-25-90-107-57-256-169-624
-17-65-54-25-194-70-265
0000000
00-1-3-3-1-6
0010.160.010.021.46
000.990.150.010.011.45
---7.00-1.00---6.00
0000000
0.080.121.080.420.650.711.66
102.07189.08141.87297.5836.74748.44487.69
0000000

CellSource Co stock margins

The CellSource Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CellSource Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CellSource Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CellSource Co's sales revenue. A higher gross margin percentage indicates that the CellSource Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CellSource Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CellSource Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CellSource Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CellSource Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CellSource Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CellSource Co Margin History

CellSource Co Gross marginCellSource Co Profit marginCellSource Co EBIT marginCellSource Co Profit margin
2026e70.61 %0 %11.25 %
2025e70.61 %0 %7.49 %
2024e70.61 %0 %9.62 %
202370.61 %27.08 %20.47 %
202271.7 %36.76 %23.82 %
202170.97 %33.96 %22.29 %
202067.85 %22.4 %14.77 %
201971.58 %20.29 %12.39 %
201872.23 %24.33 %15.95 %
201757.78 %30.66 %21.46 %

CellSource Co Stock Sales Revenue, EBIT, Earnings per Share

The CellSource Co earnings per share therefore indicates how much revenue CellSource Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CellSource Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CellSource Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CellSource Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CellSource Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CellSource Co Revenue, EBIT and net profit per share

DateCellSource Co Sales per ShareCellSource Co EBIT per shareCellSource Co Earnings per Share
2026e278.56 undefined0 undefined31.34 undefined
2025e243.27 undefined0 undefined18.23 undefined
2024e223.32 undefined0 undefined21.48 undefined
2023234.18 undefined63.42 undefined47.93 undefined
2022222.45 undefined81.77 undefined52.98 undefined
2021152.14 undefined51.67 undefined33.91 undefined
202096.99 undefined21.72 undefined14.33 undefined
2019123.43 undefined25.04 undefined15.29 undefined
201893.57 undefined22.77 undefined14.92 undefined
201740.05 undefined12.28 undefined8.6 undefined

CellSource Co business model

CellSource Co is one of the most popular companies on Eulerpool.com.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

CellSource Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

CellSource Co historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

CellSource Co shares outstanding

The number of shares was CellSource Co in 2023 — This indicates how many shares 19.261 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CellSource Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CellSource Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CellSource Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CellSource Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CellSource Co stock splits

In CellSource Co's history, there have been no stock splits.

CellSource Co dividend history and estimates

In 2023, CellSource Co paid a dividend amounting to 5 JPY. Dividend means that CellSource Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for CellSource Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify CellSource Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating CellSource Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

CellSource Co Dividend History

DateCellSource Co Dividend
20235 undefined
CellSource Co does not pay out any dividends.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for CellSource Co.

CellSource Co shareholders

%
Name
Stocks
Change
Date
36.22172 % Yamakawa (Masayuki)7,173,90004/30/2024
9.59732 % Serial Incubate KK1,900,80004/30/2024
6.84658 % Tsumamoto (Masato)1,356,00004/30/2024
2.65027 % Baillie Gifford & Co.524,90008/31/2024
1.99742 % Nomura Asset Management Co., Ltd.395,6003,3009/30/2024
1.36373 % Nikko Asset Management Co., Ltd.270,0931,2009/30/2024
0.92226 % Daiwa Asset Management Co., Ltd.182,6592,8009/30/2024
0.83310 % Meiji Yasuda Asset Management Company Ltd.165,000106,0008/31/2023
0.59377 % SBI Securities Co., Ltd.117,600117,6004/30/2024
0.47044 % Asset Management One Co., Ltd.93,17409/30/2024
1
2
3
4
5
...
6

Most common questions regarding CellSource Co

What is the P/E ratio of CellSource Co 2024?

The CellSource Co P/E ratio is 51.03.

What is the P/S ratio of CellSource Co 2024?

The CellSource Co P/S ratio is 4.91.

What is the Quality Investing of CellSource Co?

The Quality Investing for CellSource Co is 4/10.

What is the revenue of CellSource Co 2024?

The expected CellSource Co revenue is 4.42 B JPY.

How high is the profit of CellSource Co 2024?

The expected CellSource Co profit is 425.41 M JPY.

What is the business model of CellSource Co

No history available for CellSource Co.

What is the CellSource Co dividend?

CellSource Co pays a dividend of 0 JPY distributed over payouts per year.

How often does CellSource Co pay dividends?

The dividend cannot currently be calculated for CellSource Co or the company does not pay out a dividend.

What is the CellSource Co ISIN?

The ISIN of CellSource Co is JP3423580004.

What is the CellSource Co ticker?

The ticker of CellSource Co is 4880.T.

How much dividend does CellSource Co pay?

Over the past 12 months, CellSource Co paid a dividend of 5 JPY . This corresponds to a dividend yield of about 0.44 %. For the coming 12 months, CellSource Co is expected to pay a dividend of 5 JPY.

What is the dividend yield of CellSource Co?

The current dividend yield of CellSource Co is 0.44 %.

When does CellSource Co pay dividends?

CellSource Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CellSource Co?

CellSource Co paid dividends every year for the past 0 years.

What is the dividend of CellSource Co?

For the upcoming 12 months, dividends amounting to 5 JPY are expected. This corresponds to a dividend yield of 0.44 %.

In which sector is CellSource Co located?

CellSource Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von CellSource Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CellSource Co from 1/1/2025 amounting to 5 JPY, you needed to have the stock in your portfolio before the ex-date on 10/30/2024.

When did CellSource Co pay the last dividend?

The last dividend was paid out on 1/1/2025.

What was the dividend of CellSource Co in the year 2023?

In the year 2023, CellSource Co distributed 0 JPY as dividends.

In which currency does CellSource Co pay out the dividend?

The dividends of CellSource Co are distributed in JPY.

All fundamentals about CellSource Co

Our stock analysis for CellSource Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CellSource Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.